Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison

Diagnostic concordance between NT-proBNP and BNP for suspected heart failure

(2018) Christopher W. Farnsworth et al.   CLINICAL BIOCHEMISTRY

Pioglitazone and bladder cancer risk: a systematic review and meta-analysis

(2018) Huilin Tang et al.   Cancer Medicine

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

(2017) David Fitchett et al.   EUROPEAN HEART JOURNAL

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure

(2017) Peter P. Swoboda et al.   Journal of the American Heart Association

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

2013 ACCF/AHA Guideline for the Management of Heart Failure

(2013) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY